

City & County of San Francisco
London N. Breed, Mayor



Office of the City Administrator
Carmen Chu, City Administrator
David Serrano Sewell, Executive Director
Office of the Chief Medical Examiner

February 22, 2024

Subject: Report on 11550 Casework – 2023

The enclosed report includes drug prevalence data on received 11550 casework in the City and County of San Francisco from August 1, 2023 to December 31, 2023. The reports are published by the Office of the Chief Medical Examiner (OCME), Forensic Laboratory Division, to further the OCME's mission to provide neutral data to inform policymakers.

Pertinent for the accurate use of this report is understanding the scope of testing leading to the summarization of the data. The OCME performs [full and comprehensive testing](#) on all 11550 casework to mitigate bias, ensure a complete toxicological profile is provided for each case, and to determine the extent of alcohol and drugs exposure within the community.

Enclosed is a detailed 11550 Data Report for 2023. Key findings were:

- One or more substances were identified in 99% of cases.
- Bromazolam was detected in 7% of cases and Xylazine was detected in 41% of cases.

Sincerely,

A handwritten signature in blue ink, appearing to read "Luke N. Rodda".

Luke N. Rodda, Ph.D. MRACI CChem
Chief Forensic Toxicologist and Director, Forensic Laboratory Division


cc: Office of the City Administrator
enclosures: 11550 Data Report – 2023




11550 Cases 2023

88 Submitted Cases

Case Submissions by Month



Drug Prevalence



Cases		Drug Class Prevalence	Cases	
(1)	82	94%	Amphetamines	Opioids 82 (23) 92%
	75	85%	Cocaine	Anesthetic 35 40%
	35	40%	Miscellaneous	Cannabis 27 31%
(9)	12	24%	Analgesics	Antihistamines 12 (1) 13%
(3)	7	11%	Benzodiazepines	Antipsychotic 7 (1) 5%
	3	3%	Antidepressant	Muscle Relaxant 2 2%
	2	2%	Anticonvulsant	

(Denotes where 2 or more of the same drug class was prevalent within same case)

Drug Prevalence	Cases
Amphetamines	
Methamphetamine	94% 83
Amphetamine	85% 75
Norephedrine/Norpseudoephedrine	77% 68
Ephedrine/Pseudoephedrine	60% 53
3,4-Methylenedioxyamphetamine (MDMA)	1% 1
Analgesics	
Acetaminophen	19% 17
Salicylic Acid	19% 17
Anesthetics	
Norlidocaine	39% 34
Lidocaine	34% 30
Anticonvulsants	
Gabapentin	2% 2
Antidepressants	
Mirtazapine	2% 2
Nordoxepin	1% 1
O-/N-Desmethyl Venlafaxine	1% 1

Drug Prevalence	Cases
Antihistamines	
Venlafaxine	1% 1
Norchlorcyclizine	13% 11
Cetirizine/Levocetirizine	5% 4
Diphenhydramine	3% 3
Doxylamine	2% 2
Antipsychotic	
9-Hydroxy Risperidone	2% 2
Olanzapine	2% 2
Norquetiapine	1% 1
Quetiapine	1% 1
Benzodiazepines	
Alprazolam	7% 6
Bromazolam	7% 6
alpha-Hydroxy Alprazolam	6% 5
7-Amino Clonazepam	2% 2
Cannabis	
Carboxy THC	34% 30



11550 Cases

2023

88 Submitted Cases

Drug Prevalence	Cases
Cocaine	
Benzoyllecgonine	82% 72
Cocaine	53% 47
meta-/para-Hydroxy Cocaine	41% 36
Norcocaine	25% 22
Anhydroecgonine Methyl Ester	16% 14
Cocaethylene	5% 4
Decongestants	
Tetrahydrozoline	1% 1
Miscellaneous	
Xylazine	41% 36
Muscle Relaxants	
N-Desmethyl Cyclobenzaprine	2% 2
Cyclobenzaprine	1% 1
Scopolamine	1% 1
Opioids	
Fentanyl	89% 78
Norfentanyl	78% 69
Acetyl Fentanyl	53% 47
Methadone	8% 7
Norbuprenorphine	8% 7
Codeine	6% 5
EDDP (Methadone Metabolite)	6% 5
Morphine	6% 5
Norcodeine	5% 4
Tramadol	5% 4
Buprenorphine	3% 3
Noroxycodone	3% 3
Dextrophan/Levorphanol	2% 2
Hydromorphone	2% 2
6-Monoacetylmorphine (6-MAM)	1% 1
Dextromethorphan/Levomethorphan	1% 1
Naloxone	1% 1
Norhydrocodone	1% 1
Noroxymorphone	1% 1
O-Desmethyl-Tramadol	1% 1